AbbVie Reports Promising New Clinical Updates. Here's What It Means for the Company's Dividend.
New cancer therapies may help fund dividend growth.
Overview
AbbVie (NYSE: ABBV) boasts a pretty attractive dividend at more than 3%.
That's significantly higher than many other blue-chip healthcare stocks, including Eli Lilly (NYSE: LLY), Johnson & Johnson (NYSE: JNJ), and Amgen (NASDAQ: AMGN), all of which yield dividends of roughly 2% or less.
Details
But dividends don't increase just because management wants them to. They rise because the business generates enough cash to support them.
Source
Originally published at www.fool.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.